GlassScriptPhysician profile
Hannah Park
NPI 1376922682
$64,665.46
in general payments reported to CMS, 2019-2025
22 companies · $59K in 2025
The $59K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.97 · 2023: $594 · 2024: $5,075 · 2025: $59K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $52K · Travel and Lodging: $8,023 · Food and Beverage: $2,660 · Consulting Fee: $1,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $52,440.00 |
| Travel and Lodging | $8,022.67 |
| Food and Beverage | $2,659.82 |
| Consulting Fee | $1,525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $63,476.56 | 2023-2025 | |
| Abbvie INC. | $296.69 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $122.21 | 2023 | Lokelma |
| Biogen, INC. | $96.21 | 2023-2025 | Vumerity, Tysabri, Leqembi |
| Ucb, INC. | $85.23 | 2023-2025 | Briviact, Fintepla |
| Lilly USA, LLC | $75.31 | 2023-2024 | Emgality, Amyvid, Kisunla |
| Alexion Pharmaceuticals, INC. | $68.34 | 2023-2024 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $59.43 | 2024 | Austedo Xr, Ajovy |
| Sk Life Science, INC. | $51.91 | 2023-2025 | |
| Merz Pharmaceuticals, LLC | $48.70 | 2024 | Inbrija, Xeomin |
| Boston Scientific Corporation | $45.82 | 2024-2025 | General - Dbs |
| Eisai INC. | $34.45 | 2023-2024 | |
| Amneal Pharmaceuticals LLC | $32.45 | 2024 | Rytary |
| Amgen INC. | $30.63 | 2023-2024 | Aimovig |
| Otsuka America Pharmaceutical, INC. | $21.86 | 2024 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $18.89 | 2024 | Ponvory |
| Novartis Pharmaceuticals Corporation | $18.50 | 2024 | |
| Genzyme Corporation | $18.39 | 2023 | |
| Currax Pharmaceuticals LLC | $17.97 | 2022 | |
| Corium, LLC | $17.22 | 2024 | Azstarys |
| Neurocrine Biosciences, INC. | $14.99 | 2023 | Ingrezza, Ongentys |
| Argenx US, INC. | $13.70 | 2024 | Vyvgart Hytrulo, Vyvgart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.